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ABSTRACT 
As a consequence of the genomic revolution, a large number of publications describing 
paroxysmal movement disorders have been published in the last few years, shedding light 
on their molecular pathology. Routine gene testing is not necessary to guide treatment for 
typical forms of paroxysmal kinesigenic dyskinesia (PKD), paroxysmal non-kinesigenic  
dyskinesia (PNKD), and episodic ataxia type 1 (EA1) or 2 (EA2). It can, however, be helpful in 
the management of atypical or complex cases, especially for genetic counselling, treatment 
strategies and the offer of preimplantation genetic diagnosis. Anti-epileptic drugs remain 
the treatment of choice for PKD and EA1, benzodiazepines are often useful for PNKD, and 
EA2 benefits from acetazolamide regardless of the genetic etiology.  
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What this paper adds: 
 A growing number of genes has been associated with classic and newly described 
paroxysmal movement disorders including PRRT2, SLC2A1, PNKD, KCNA1, CACNA1A, 
CACNB4, KCNMA1, SLC1A3, SCN2A, KCNA2, SCN1A, ATP1A2, ATP1A3, ADCY5, GNAO1. 
 Paroxysmal movement disorders share common mechanisms and clinical features with 
other neurologic paroxysmal phenomena including epilepsy and migraine. 
 
 
MANUSCRIPT 
INTRODUCTION 
Primary paroxysmal dyskinesias are distinguished from episodic ataxias on clinical grounds 
as the latter involve episodes of incoordination and imbalance, but not dyskinesias. 
However, recent genetic findings have led to the two different clinical presentations being 
considered together1. They are characterized by episodic symptoms that usually begin in 
childhood or adolescence and tend to improve or even resolve later in life.  
Most of the identified genetic mutations leading to paroxysmal disorders are related to 
membrane proteins expressed in neurons and often linked with the regulation of cellular 
excitability. This review focuses on how new genetic findings have influenced the nosology 
  
of paroxysmal movement disorders and treatment strategies. A detailed review of each 
gene is available from (https://www.ncbi.nlm.nih.gov/books/NBK1116/).  
Structural damage to the CNS can manifest as paroxysmal movement disorder in an 
exceedingly small proportion of patients. Nevertheless, because true primary paroxysmal 
movement disorders are rare, secondary paroxysmal movement disorders, which include 
demyelination, tumours, stroke and neurodegenerative diseases need to be clearly 
distinguished as part of the diagnostic process. Functional (psychogenic) paroxysmal 
movement disorders are not uncommon and should be promptly recognized and 
appropriately treated. Motor stereotypies, complex motor tics, developmental movement 
disorders (e.g. gratification phenomenon) and epileptic seizures need to be considered in 
the differential diagnosis, in particular in younger children.  
PHENOTYPES 
The clinical phenomenology of the primary paroxysmal dyskinesias was largely delineated 
and described in the second half of the twentieth century and has subsequently been 
embellished by advances in genetics particularly in the last decade. 
INITIAL DESCRIPTIONS 
Although descriptions of attacks of paroxysmal kinesigenic dyskinesia actually date as far 
back as 18922, it was Mount and Reback3 who described the first family with paroxysmal 
attacks of a movement disorder characterized by a combination of dystonia and 
choreoathetosis, which could be precipitated by alcohol, coffee, tea, fatigue, and smoking. 
The names “paroxysmal choreoathetosis of Mount and Reback”, “familial paroxysmal 
choreoathethosis” and others were used until 1967 when Kertesz4 described very clearly 
that some patients (but not all) could present with “kinesigenic” triggers: attacks could be 
caused by sudden movement, like suddenly standing up from a chair, or suddenly starting to 
run after being still for a while. Various names were used over time to differentiate between 
the different forms, with a general agreement that “kinesigenic” and “non-kinesigenic” 
dyskinesias seemed to be different conditions, to which some applied the terms 
“paroxysmal kinesigenic choreoathetosis (PKC) and paroxysmal dystonic choreoathetosis 
(PDC), both no longer in use.  
  
CURRENT CLASSIFICATIONS 
By 1995 Dermirkiran and Jankovic5 published the classification that is mostly used today 
based on the analysis of 46 patients. In their study, they applied and revised the prevailing 
criteria previously used for classification: i) type of triggers ii) duration of attacks, iii) 
existence of a family history iv) presence of previous or ongoing CNS injury. This series 
reflects usual findings in clinics elsewhere: secondary paroxysmal dyskinesias were more 
frequent than primary, and the frequency of non-kinesigenic dyskinesia was almost double 
that of kinesigenic. The authors classified paroxysmal dyskinesias into kinesigenic 
(paroxysmal kinesigenic dyskinesia, PKD), non-kinesigenic (PNKD), exertion induced (PED, 
which some call also “exercise-induced”), and hypnogenic (PHD). PHD had been described in 
1981 by Lugaresi and Cirignotta6 as nocturnal attacks of dystonia during non-REM sleep and 
without detectable epileptiform activity on concomitant EEG; these were also called 
“nocturnal hypnogenic paroxysmal dystonia” or “nocturnal paroxysmal dystonia” until in 
1990 the same group established the epileptic nature of such episodes in three patients7. 
Currently, in almost all patients, this condition is no longer considered a dyskinesia but a 
familial form of frontal lobe epilepsy in which frontal lobe discharges may not be easily 
detected with conventional EEG, and it has been renamed nocturnal frontal lobe epilepsy 
(NFLE) which can be caused by mutations in several different genes (NFLE phenotypic series 
- http://omim.org/phenotypicSeries/PS600513). 
PAROXYSMAL KINESIGENIC DYSKINESIA (PKD) 
In 2004 Bruno and colleagues8 reviewed clinical details of a multicentre retrospective cohort 
of 121 affected individuals from 73 kindreds with PKD, and proposed the diagnostic criteria 
that is still largely used today to diagnose primary PKD: (1) Identified kinesigenic trigger for 
the attacks; (2)Short duration of attacks (<1 minute); (3) No loss of consciousness or pain 
during attacks; (4) Exclusion of other organic diseases and normal neurologic examination; 
(5) Control of attacks with phenytoin or carbamazepine, if tried; (6) Age at onset between 1 
and 20 years, if no family history of PKD. These criteria are summarized in Figure 1 (insert A). 
In their own cohort, 95 patients had what they called “classic PKD” and fulfilled the criteria, 
while the remaining ones had atypical clinical features including 12 patients with infantile 
(<1y of age) onset of PKD, and 14 patients in an “outlier group” in which alternative 
diagnosis were considered including psychogenic movement disorder, non-kinesigenic or 
  
exercise-induced paroxysmal dyskinesia. They also highlighted that linkage analysis had 
associated a specific region of chromosome 16 with both PKD and infantile convulsion with 
choreoathetosis (ICCA, OMIM # 602066, ”#” indicating a phenotype entry in OMIM), 
suggesting that PKD, ICCA and infantile convulsions could all be part of the phenotypic 
spectrum from mutations in the same gene.  
PAROXYSMAL NON-KINESIGENIC DYSKINESIA (PNKD) 
The phenotype of PNKD continues to evolve and presents with greater variability than PKD, 
and much more often is secondary to neurological conditions. After the discovery of the 
mutations on a gene causing classic familial PNKD in various families (see below), Bruno and 
others9 reviewed 49 patients from eight mutation positive kindreds, and 22 patients from 
six kindreds who were mutation negative. The criteria they suggested for the diagnosis of 
classic PNKD were: (1) Hyperkinetic involuntary movement attacks, with dystonia, chorea, or 
combination of these, typically lasting 10 minutes to 1 hour, but up to 4 hours (2) Normal 
neurologic examination between attacks, and exclusion of secondary causes (3) Onset of 
attacks in infancy or early childhood, (4) Precipitation of attacks by caffeine and alcohol 
consumption, (5) Family history of movement disorder meeting Criteria 1 through 4. These 
are summarized in Figure 1 (insert B), which highlights that in addition to different triggers, 
PNKD attacks are longer than PKD attacks, less frequent, and respond to different 
medications.  
PAROXYSMAL EXERCISE-INDUCED DYSKINESIA (PED) 
Paroxysmal exercise-induced dyskinesia (PED) was first brought to attention in 1977 by 
Lance10 who reported a family in which 3 affected members (grandfather, mother and 
daughter) all suffered from episodes of dystonia with superimposed mild chorea, only after 
prolonged exercise, but no other triggers such as sudden movement, alcohol or tobacco. He 
also noted that the duration of the episodes (mostly between 5 and 30 minutes) were 
longer than PKD, but shorter than PNKD attacks. In one person who had tried medication, 
neither carbamazepine, phenytoin or clonazepam worked. It took another 7 years until 
Plant et al11 described the second family (mother and daughter) with what they termed 
“Familial paroxysmal dystonia induced by exercise”, and demonstrated that the dystonic 
movements could also be precipitated by prolonged sensory stimulation either with passive 
movement or vibration. Although the episodes were reported in the lower limbs in both 
  
families reported then, Plant could elicit PED in the upper limbs with prolonged exercise or 
sensory stimulation, and reasoned that the lower limbs predominance could be situational 
because they are more often under prolonged exercise. There was family history of 
epilepsy. No formal diagnostic criteria were proposed, instead the clinical features described 
by Plant11 and Lance10 are still used as guidelines to diagnose this rather rare condition; 
these are also summarized in Figure 1 (insert C).   
GENOTYPES AND EXPANDED PHENOTYPES 
The genes underlying the main types of episodic ataxia (EA) were described in the 1990s. EA 
type 1 (EA1 OMIM # 160120), which causes short episodes of ataxia (seconds to minutes) 
several times per week and interictal myokymia, is associated with mutations in a gene that 
codes for one of the potassium channels, KCNA1 (K stands for potassium, CN for channel, 
and A1 is the type of potassium channel subunit, which can form homomeric or heteromeric 
channels).  
In EA2 (OMIM # 108500) episodes are longer, less frequent, lasting up to hours,  and 
interictal nystagmus (and not myokymia) is often seen. EA2 is associated with mutations in 
the gene  for one of the subunits of the calcium channel, CACNA1A (CA stands for calcium, 
CN for channel, and A1A is a subunit of the channel, which is a heteromer composed of 
various different subunits coded by different genes). CACNA1A was also associated with 
other paroxysmal disorders including hemiplegic migraine (OMIM # 141500), epilepsy 
(OMIM # 617106 and others), benign paroxysmal torticollis of childhood and paroxysmal 
tonic upward gaze, reflecting phenotypic pleiotropy: the fact that mutations in one single 
gene can cause several distinct phenotypes. In addition, a different type of mutation on 
CACNA1A causing trinucleotide repeat also caused a non-paroxysmal disease: progressive 
cerebellar atrophy as in spinocerebellar atrophy type 6 (SCA6, OMIM # 183086).  
The gene underlying classic cases of PNKD was described in 2004 as MR-1 
(myofibrillogenesis regulator 1, OMIM *609023, ”*” indicating a gene entry in OMIM) later 
renamed PNKD, which is the currently accepted name. Other names used for this gene or 
locus include MR1; MR-1; PDC; DYT8; FPD1; BRP17; PKND1; FKSG19; TAHCCP2; KIPP1184. 
Unlike CACNA1A this gene is not associated with significant phenotypic pleiotropy, and in 
some cohorts was found to underlie the majority of classical familial cases of PNKD. Later in 
  
2008 various cases of PED were shown to be caused by mutations in the gene GLUT-1 
(glucose transporter type 1), now officially called SLC2A1 (OMIM * 138140). SLC stands for 
solute carrier, and 2A1 for the family number 2, member number 1 in the family. The 
current nomenclature for genes coding non-active transporters is SLC. SLC2A1 (which many 
clinicians still continue to call GLUT-1) was described previously in association with infantile 
epilepsy with low CSF glucose, initially described by De Vivo in 199112. Today it is apparent 
that although isolated PED caused by SLC2A1 mutations is rare, episodes of PED in sufferers 
from GLUT-1 deficiency syndrome (GDS) are common, but often go unnoticed in the setting 
of epilepsy and other more severe findings13. Isolated dystonia after exercise (usually 
affecting only the lower limbs) has also been observed in carriers of mutations causing early 
onset parkinsonism (such as PARKIN, OMIM * 602544) or dopa-responsive dystonia (such as 
GCH1, OMIM * 602544), but are rather unusual initial presentations of these conditions.  
The gene underlying most cases of PKD was the latest one to be identified and was 
described at a time when genomic technology had advanced significantly, therefore 
allowing for a very swift description of a  vast array of disparate phenotypes, demonstrating 
impressive phenotypic pleiotropy. PRRT2 (OMIM * 614386) which stands for Proline-Rich 
Transmembrane Protein 2 codes for a transmembrane protein whose function is relatively 
unknown, but seems to be involved in synaptic transmission. Between 2011 and 2013 it was 
associated not only with PKD, but also shown to be the  cause for the majority of cases of 
benign infantile familial seizures (OMIM # 605751) and infantile convulsions with 
paroxysmal choreoathetosis (ICCA, OMIM # 602066), and as a frequent cause of hemiplegic 
migraine, in addition to one sporadic case of benign paroxysmal torticollis of infancy, and a 
few cases of episodic ataxia (some with homozygous mutation and accompanying features 
including developmental delay or epilepsy). The odyssey of PRRT2 into one of the most 
notable examples of phenotypic pleiotropy has been chronicled in various review articles 
and commentaries14–18. Figure 2 compares the phenotypic pleiotropy seen in PRRT2 with 
that of CACNA1A, KCNA1 and SLC2A1.  
IMPACT ON PATIENT MANAGEMENT 
Given the significant phenotypic pleiotropy observed in genetic paroxysmal movement 
disorders, and the overlap with clinical spectrums associated with other genes, history 
  
taking must encompass not only one type of episode, but also any history of the various 
possible paroxysmal phenomena in the patient and family members. Paroxysmal 
phenomena in these overlapping syndromes include: paroxysmal weakness, paroxysmal 
ataxia, paroxysmal chorea, paroxysmal dystonia, paroxysmal myokymia, paroxysmal eye 
movement abnormalities, migraine, and epilepsy. Table 1 provides a summary of clinical 
information that might suggest a particular gene is involved. 
The diagnosis of paroxysmal conditions is often hampered by the lack of findings on 
neurological examination. Therefore, history and when possible video recordings of 
paroxysmal events are often the most useful tool. It can also be useful to ask the patient to 
mimic their actual episodes. Videos may be very useful but also have many caveats. 
Whenever possible they should be obtained with appropriate settings (frame, angle, 
lighting, duration, screen resolution, etc) and the largest number of episodes possible. This 
can help differentiate between dyskinesias (dystonia and chorea) and ataxia, although gait 
ataxia can only be seen if the patient is filmed while walking, and ataxic uncoordinated 
movements in children can be confused with dyskinesias. Older children will report dizziness 
and vertigo, but smaller children may not be able to. Both episodic ataxias and paroxysmal 
dyskinesias tend to start in childhood or teenage years, rendering the initial diagnosis 
challenging.  
Myokymia may be difficult to document and sometimes to interpret, but is a useful finding. 
It is a hallmark of EA1 caused by KCNA1 mutations, and some family members may present 
with isolated myokymia. Familial Dyskinesia with Facial Myokymia (OMIM # 606703) which 
is caused by mutations on the ADCY5 gene (OMIM * 600293) and presents with facial 
movements now believed to represent facial dyskinesia (chorea) or facial myoclonus, and 
not true myokymia19. ADCY5 mutations present with a broad phenotypic spectrum and can 
initially manifest with paroxysmal dyskinesias (often sleep-related), making for an important 
differential diagnosis20. 
It is paramount to differentiate between episodes of positive symptoms (like dystonia or 
chorea) from negative symptoms, in particular paroxysmal hemiplegia which is seen in 
hemiplegic migraine and also in alternating hemiplegia of childhood (AHC, OMIM # 104290), 
both conditions which show clinical and genetic overlap with paroxysmal dyskinesia. 
  
Mutations in PRRT2, the main known cause of classic PKD can also cause hemiplegic 
migraine, and this condition may co-exist within families or individuals. Mutations in ATP1A3 
(OMIM * 182350), the causative gene for AHC, are associated with a broad spectrum of 
phenotypic manifestation including episodes of hemiplegia and hemidystonia (isolated of 
combined), in addition to other features like developmental delay or loss of milestones. 
ATP1A3 mutations also cause rapid onset dystonia parkinsonism (RPD, previously called 
DYT12, OMIM # 128235), cerebellar ataxia, areflexia, pes cavus, optic atrophy, and 
sensorineural hearing loss (CAPOS, OMIM # 601338). Although RDP and CAPOS themselves 
do not manifest with paroxysmal dystonia, there is a growing notion that ATP1A3 mutations 
cause various intermediate phenotypes with clinical overlap21,22.  
Although genetic testing is advisable, it is not always necessary for the treatment of 
patients, but can help define the prognosis, and  aid in reproductive counselling, which is 
particularly important for conditions which carry greater disability like ATP1A3 phenotypes, 
which can be inherited or are often caused by de-novo mutations, in which case they bear 
low recurrence risk except when there is underlying germline mosaicism. Figure 3 shows 
how phenotypic spectrums for various paroxysmal movement disorders overlap with 
migraine and epilepsy. Because the sequential testing for multiple genes is usually more 
expensive than a gene panel, most experts these days recommend that either gene panel or 
exome sequencing might be preferable when there is not a very strong suspicion for a single 
gene. Gene panels are usually designed by different labs based on a central phenotype (like 
“dystonia”, “chorea”, “paroxysmal movement disorder”, etc) while exome sequencing will 
look at sequencing changes in the exons of roughly 20,000 genes. The main advantage of 
the panels over exome sequencing is that many include coverage for deletions or 
duplications, which do not alter sequence per se, and are not detected by standard 
sequencing techniques. Therefore, knowledge of the phenotypes, genotypes, and 
techniques is necessary before requesting the test, and when necessary the opinion of a 
specialist in neurogenetics or movement disorders is of great value. 
Treatment for paroxysmal movement disorders remains mostly unchanged, and with the 
exception of a randomized controlled trial for 4-aminopyridine in EA223, all options are 
based on observational studies, expert consensus or anecdotal evidence, and are mainly 
directed at the phenotype and not genotype. There is emerging evidence that triheptanoin 
  
might be useful in SLC2A1-related PED24. However, because a therapeutic trial with any of 
the available options (acetazolamide, anti-epileptic drugs, benzodiazepines, levodopa, 
ketogenic diet, and potentially triheptanoin) is unlikely to support a specific diagnosis in 
patients with PED, diagnosis usually requires additional testing including CSF glucose and 
neurotransmitters, erythrocyte glucose uptake, erythrocyte GLUT-1 expression or testing for 
SLC2A1 mutations25. This is likely due to a combination of the rarity of these conditions, and 
the fact that effective treatments were described before the era of genomics: PKD responds 
to low dose carbamazepine (or phenytoin), PNKD often responds to benzodiazepines, and 
PED tends to respond poorly to medication, although benzodiazepines, levodopa, 
acetazolamide, antiepileptic drugs and even ketogenic diet can be tried depending on 
severity1. A few cases of good response to deep brain stimulation have been reported in 
refractory severe PNKD26,27 and also on life-threatening exacerbations of dyskinesias in 
patients carrying mutations in GNAO128. GNAO1 mutations have recently been described as 
a cause of early life movement disorder with or without epileptic encephalopathy, often 
wrongly labelled as “dyskinetic cerebral palsy” with episodic “dyskinetic storms” with poor 
response to oral medications. Acetazolamide, an carbonic anhydrase inhibitor which was 
initially used for epilepsy as an alternative to the ketogenic diet, remains the standard 
treatment for EA2, in addition to flunarizine or 4-aminopyridine; EA1 responds to 
carbamazepine, valproic acid and acetazolamide, but the response to acetazolamide in EA1 
is not as dramatic as in EA21,29. Therefore, although genetic testing might be useful for 
various different reasons, it is not necessary to target initially pharmacotherapy in patients 
with classic phenotypes.  
CONCLUSION 
Although genetics has so far had relatively little impact on the treatment of primary 
paroxysmal movement disorders it has played a significant part in changing our 
understanding of the likely mechanisms involved in their causation. It is to be hoped that as 
a greater understanding of the chemical processes involved in the mediation of this 
fascinating group evolves more specific and efficacious therapies can be developed. 
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FIGURES AND LEGENDS 
 
 
Figure 1 – Classic phenotypes of primary paroxysmal dyskinesia 
 
 
 
Legend: this figure summarizes the main clinical criteria used to differentiate between the 3 
classic phenotypes of paroxysmal dyskinesia. All criteria require exclusion of secondary causes 
of paroxysmal dyskinesia such as brain lesions, metabolic derangements, etc. Although the 
term primary is used, classic paroxysmal dyskinesia is often familial, and mostly cause by 
known genetic mutations. PED = paroxysmal exercise-induced dyskinesia, PKD = paroxysmal 
kinesigenic dyskinesia, PNKD = paroxysmal non-kinesigenic dyskinesia, h = hours, min = 
minutes, y = years. 
 
 
 
  
  
Figure 2 - Phenotypic pleiotropy in genes associated with episodic ataxias 
 
 
 
Legend: this figure summarizes the main phenotypes associated with PRRT2 (upper left figure) 
and how it compares with that of CACNA1A (lower left) and KCNA1 (upper right), and with the 
summarized phenotypic spectrum of SLC2A1 (lower right). PRRT2, CACNA1A and KCNA1 have 
been associated with discrete phenotypes as well with intermediate phenotypes, suggesting 
there is a large spectrum of clinical manifestations like SLC2A1. Although there is significant 
overlap, clinical features in history and examination (or video documentation) may be enough 
to differentiate between the main phenotypes and guide management without need for 
genetic diagnosis. Age of onset for almost all paroxysmal conditions associated with these 
genes have onset in infancy (BPT, infantile convulsions, epileptic encephalopathy) or 
childhood/adolescence (EAs, PKD) but they may occasionally start in adult life (PED, epilepsy, 
progressive ataxia).  
 
  
  
Figure 3 - Phenotypic overlap for genes associated with paroxysmal movement disorders 
 
 
 
Legend: this figure summarizes how the genes associated with paroxysmal movement 
disorders (paroxysmal dyskinesias and episodic ataxias) can also manifest with other 
paroxysmal episodes including hemiplegic migraine and epilepsy. Only epilepsy genes 
associated with other paroxysmal events (e.g. migraine, movement disorder) are included in 
this figure.  
 
  
TABLES  
Table 1 – Clinical features of paroxysmal dyskinesia associated with different genes 
Legend: this table summarizes the main clinical features in paroxysmal dyskinesia which are suggestive of association with mutations in a 
particular gene.  
 
Genes  Suggestive clinical features in patient or family members  
 PRRT2 More common phenotypes: classic paroxysmal kinesigenic dyskinesia (PKD), benign familial infantile seizures, hemiplegic migraine 
PKD with short duration (<1min), high frequency (>daily), often asymmetric or unilateral, but also bilateral; may be chorea/dystonia/mix; may 
present sensory aura before attack; may present episodes at rest; excellent response to low dose antiepileptic (carbamazepine and phenytoin are 
the most used, in this order); onset on the 2nd decade of life and improvement or remission on the 4th decade of life. Family history of epilepsy or 
migraine is common. All phenotypes can be inherited as autosomal dominant traits. 
SLC2A1 More common phenotypes: infantile epilepsy, classic paroxysmal exercise-induced dyskinesia (PED), PED associated with epilepsy. 
PED after exercise, often in lower limbs (probably because they are more often exercised for prolonged periods); dystonia > chorea; low glucose CSF 
in some but not all patients; usually does not respond well to antiepileptic drugs; age of onset is quite variable from childhood to adulthood. Family 
history of epilepsy is common. Variable penetrance and variable expressivity.  
PNKD More common phenotype: paroxysmal non-kinesigenic dyskinesia (PNKD) 
PNKD starting in infancy -childhood; mix of chorea and dystonia; attacks lasting between minutes to 1h, not triggered by sudden movement or 
exercise, but triggered by caffeine or alcohol intake, as well as emotional stress; response to benzodiazepines; not associated with epilepsy.  
PARKIN, GCH1 More common phenotypes: dopa responsive dystonia, levodopa responsive parkinsonism 
PED with dystonic features is a rare initial presentation, usually in the lower limbs, with excellent response to levodopa; family history for 
consanguinity for Parkin, GCH1 can have autosomal dominant or rarely a recessive inheritance; Parkin usually starts in young adulthood, GCH1 starts 
in children. Family history for dystonia or parkinsonism can happen for both genes. Not associated with epilepsy.  
 ACDY5 More common phenotypes: familial dyskinesia with facial myokymia 
Paroxysmal dyskinesia brought on by stress may be the initial presentation, but older family members may present with persistent dyskinesias 
(chorea and dystonia). Abnormal facial movements (myoclonus/dyskinesia, not truly myokymia). Dyskinesias tend to improve with adult life. Patients 
may present with history of developmental delay or hypotonia. Likely to have phenotypic pleiotropy and reduced penetrance due to mosaicism 
which are still being described in the literature.  
ATP1A3 More common phenotypes: alternating hemiplegia of childhood (AHC), rapid onset dystonia parkinsonism (RDP), cerebellar ataxia, areflexia, pes 
cavus, optic atrophy, and sensorineural hearing loss (CAPOS) and intermediate phenotypes 
AHC starts in infancy and presents with episodes of hemiplegia and often hemidystonia. It usually evolves with epilepsy and loss of developmental 
milestones, and often persistent movement disorder. The RDP phenotype does not usually cause paroxysmal dystonia, but persistent dystonia 
and/or parkinsonism of subacute onset. Paroxysmal ataxia, later on becoming persistent is also described in ATP1A3 mutations.  
 
